1 July 2026
Research grade manufacturing continues to generate revenue
Our GLP research grade facility continues to supply custom oligonucleotides to research, diagnostic and early development customers.
Investors Centre
An integrated life sciences company. AI Drug Discovery for the Next Generation of RNA Medicines.
Information for investors in Syngenis, an integrated life sciences company operating one platform across three connected pillars.
Investors Centre
Company information, governance and announcements.
Syngenis Labs Ltd is an integrated life sciences company building sovereign RNA and DNA discovery, manufacturing and clinical capability in Australia. This centre brings together company information, corporate governance documents and announcements for interested parties.
6
Connected pillars
1
Australia's only commercial RNA facility
43.5c
Per eligible R&D dollar
AU
Onshore, sovereign capability
Over 21 RNA and DNA medicines have already received FDA approval, treating patients across rare genetic disease, cardiovascular conditions, and metabolic disorders — including Spinraza (spinal muscular atrophy), Amvuttra (ATTR amyloidosis), Leqvio (high cholesterol), and Onpattro (hereditary transthyretin amyloidosis). This is a proven drug class. The challenge and opportunity now lies in manufacturing capacity, discovery speed, and scale — and that is precisely what Syngenis is built to deliver.
Why Syngenis
Why Syngenis.
An integrated platform across three pillars, Australia's only commercial RNA manufacturing facility, revenue generating research grade manufacturing today, a world class scientific and advisory bench, and a sovereign, on home soil model. This overview is provided for information only.
One integrated platform
Three connected pillars on a single engine, so value compounds across the whole business.
Sovereign capability
Australia's only commercial RNA facility, onshore, with a world leading R&D incentive.
Revenue generating today
Research grade manufacturing is operational and generating revenue now, with GMP targeted operational from January 2027.
World class bench
A scientific and advisory bench that includes the inventor of the chemistry behind the field.
Corporate governance
Corporate governance.
Our governance documents are available to download directly.
Announcements
Announcements and updates.
15 May 2026
First AI discovered candidate enters laboratory validation
The first candidate designed end to end by Discovery AI has completed the discovery to laboratory workflow and entered validation.
10 March 2026
GMP, human grade facility in build
Construction continues on our GMP, human grade DNA and RNA manufacturing facility, targeted for 2027.
Sample announcements. The public Investors Centre is kept free of confidential capital raise material; any offer documents are handled through the proper private, compliant channel.
Work with us
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.
One Platform. Three Connected Pillars.